scholarly journals Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies

2013 ◽  
Vol 9 (4) ◽  
pp. 834-840 ◽  
Author(s):  
Mark Jit ◽  
Anthony T. Newall ◽  
Philippe Beutels
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Ausenda Machado ◽  
Irina Kislaya ◽  
Amparo Larrauri ◽  
Carlos Matias Dias ◽  
Baltazar Nunes

Abstract Background All aged individuals with a chronic condition and those with 65 and more years are at increased risk of severe influenza post-infection complications. There is limited research on cases averted by the yearly vaccination programs in high-risk individuals. The objective was to estimate the impact of trivalent seasonal influenza vaccination on averted hospitalizations and death among the high-risk population in Portugal. Methods The impact of trivalent seasonal influenza vaccination was estimated using vaccine coverage, vaccine effectiveness and the number of influenza-related hospitalizations and deaths. The number of averted events (NAE), prevented fraction (PF) and number needed to vaccinate (NVN) were estimated for seasons 2014/15 to 2016/17. Results The vaccination strategy averted on average approximately 1833 hospitalizations and 383 deaths per season. Highest NAE was observed in the ≥65 years population (85% of hospitalizations and 95% deaths) and in the 2016/17 season (1957 hospitalizations and 439 deaths). On average, seasonal vaccination prevented 21% of hospitalizations in the population aged 65 and more, and 18.5% in the population with chronic conditions. The vaccination also prevented 29% and 19.5% of deaths in each group of the high-risk population. It would be needed to vaccinate 3360 high-risk individuals, to prevent one hospitalization and 60,471 high-risk individuals to prevent one death. Conclusion The yearly influenza vaccination campaigns had a sustained positive benefit for the high-risk population, reducing hospitalizations and deaths. These results can support public health plans toward increased vaccine coverage in high-risk groups.


PLoS Medicine ◽  
2015 ◽  
Vol 12 (5) ◽  
pp. e1001829 ◽  
Author(s):  
Aronrag Meeyai ◽  
Naiyana Praditsitthikorn ◽  
Surachai Kotirum ◽  
Wantanee Kulpeng ◽  
Weerasak Putthasri ◽  
...  

Vaccine ◽  
2014 ◽  
Vol 32 (46) ◽  
pp. 6075-6083 ◽  
Author(s):  
Adriaan Blommaert ◽  
Joke Bilcke ◽  
Yannick Vandendijck ◽  
Germaine Hanquet ◽  
Niel Hens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document